• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

静脉注射后醋丁洛尔的处置情况。

Acebutolol disposition after intravenous administration.

作者信息

Meffin P J, Winkle R A, Peters F A, Harrison D C

出版信息

Clin Pharmacol Ther. 1977 Nov;22(5 Pt 1):557-67. doi: 10.1002/cpt1977225part1557.

DOI:10.1002/cpt1977225part1557
PMID:913023
Abstract

The disposition of acebutolol has been studied following intravenous doses of 0.25 to 1.0 mg/kg in 9 healthy subjects using a specific chromatographic assay to determine concentrations of drug in blood. The mean blood clearance was 6.55 ml/min/kg and the mean renal clearance, 2.68 ml/min/kg. Blood clearance was found to have a coefficient of variation of 14% for the group, to be independent of dose, and to remain essentially constant over approximately 3 wk. The fraction of the dose excreted in the urine unchanged was 0.405. Data were fitted to an equation for a two-compartment model. The mean fast and slow half-lives were 6.08 and 156.8 min, respectively. The volume of the central compartment was 0.223 L/kg, and the volume of distribution at steady-state was 1.165 L/kg. The fraction of acebutolol unbound to plasma proteins was 0.743 and was independent of drug concentration in the range examined. Data obtained from 15-min infusions were used to predict plateau blood concentrations with good accuracy during an 8-hr dosage regimen.

摘要

在9名健康受试者中,静脉注射剂量为0.25至1.0mg/kg的醋丁洛尔后,采用特定的色谱分析法测定血液中的药物浓度,对醋丁洛尔的处置情况进行了研究。平均血液清除率为6.55ml/(min·kg),平均肾脏清除率为2.68ml/(min·kg)。发现该组的血液清除率变异系数为14%,与剂量无关,并且在大约3周内基本保持恒定。以原形经尿液排泄的剂量分数为0.405。数据拟合为二室模型方程。平均快半衰期和慢半衰期分别为6.08分钟和156.8分钟。中央室容积为0.223L/kg,稳态分布容积为1.165L/kg。未与血浆蛋白结合的醋丁洛尔分数为0.743,在所研究的浓度范围内与药物浓度无关。在8小时给药方案期间,利用15分钟输注获得的数据能够准确预测稳态血药浓度。

相似文献

1
Acebutolol disposition after intravenous administration.静脉注射后醋丁洛尔的处置情况。
Clin Pharmacol Ther. 1977 Nov;22(5 Pt 1):557-67. doi: 10.1002/cpt1977225part1557.
2
Observations on the pharmacokinetics of acebutolol.醋丁洛尔的药代动力学观察
Clin Pharmacol Ther. 1976 Apr;19(4):416-20. doi: 10.1002/cpt1976194416.
3
The influence of renal function on plasma levels and urinary excretion of acebutolol and its main N-acetyl metabolite.肾功能对醋丁洛尔及其主要N-乙酰代谢产物的血浆水平和尿排泄的影响。
Clin Nephrol. 1982 Aug;18(2):88-94.
4
Dose-dependent acebutolol disposition after oral administration.口服给药后醋丁洛尔的剂量依赖性处置。
Clin Pharmacol Ther. 1978 Nov;24(5):542-7. doi: 10.1002/cpt1978245542.
5
Pharmacokinetics and bioavailability of diacetolol, the main metabolite of acebutolol.醋丁洛尔的主要代谢产物双醋洛尔的药代动力学和生物利用度。
Eur J Clin Pharmacol. 1981 Mar;19(4):287-92. doi: 10.1007/BF00562806.
6
Quantitation in plasma and urine of acebutolol and a major metabolite with preliminary observations on their disposition kinetics in man.醋丁洛尔及其主要代谢产物在血浆和尿液中的定量分析以及对其在人体处置动力学的初步观察。
Res Commun Chem Pathol Pharmacol. 1976 Sep;15(1):31-51.
7
The pharmacokinetics of acebutolol in man, following the oral administration of acebutolol HCl as a single dose (400 mg), and during and after repeated oral dosing (400 mg, b.d.).盐酸醋丁洛尔单次口服给药(400毫克)后,以及多次口服给药期间和之后(400毫克,每日两次)在人体中的药代动力学。
Biopharm Drug Dispos. 1981 Apr-Jun;2(2):103-14. doi: 10.1002/bdd.2510020202.
8
[Pharmacokinetics of acebutolol].醋丁洛尔的药代动力学
Nouv Presse Med. 1975 Dec 31;4(46 Suppl):3223-8.
9
[Study of acebutolol dialysis and pharmacokinetic data in patients with renal insufficiency undergoing hemodialysis].[对接受血液透析的肾功能不全患者进行醋丁洛尔透析及药代动力学数据的研究]
Nouv Presse Med. 1975 Dec 31;4(46 Suppl):3228-33.
10
Plasma and urine concentrations of acebutolol and its acetyl metabolite in patients with renal functional impairment.肾功能损害患者中醋丁洛尔及其乙酰代谢物的血浆和尿液浓度。
N Z Med J. 1980 Apr 23;91(658):289-91.

引用本文的文献

1
Extracorporeal treatment for poisoning to beta-adrenergic antagonists: systematic review and recommendations from the EXTRIP workgroup.体外治疗β-肾上腺素能拮抗剂中毒:EXTRIP 工作组的系统评价和建议。
Crit Care. 2021 Jun 10;25(1):201. doi: 10.1186/s13054-021-03585-7.
2
Exploring the Feasibility of Biowaiver Extension of BCS Class III Drugs with Site-Specific Absorption Using Gastrointestinal Simulation Technology.利用胃肠道模拟技术探索具有部位特异性吸收的BCS III类药物生物豁免扩展的可行性。
Eur J Drug Metab Pharmacokinet. 2017 Jun;42(3):471-487. doi: 10.1007/s13318-016-0361-2.
3
Pharmacokinetics of acebutolol in patients with all grades of renal failure.
醋丁洛尔在各程度肾衰竭患者中的药代动力学
Eur J Clin Pharmacol. 1980 May;17(5):339-48. doi: 10.1007/BF00558446.
4
Blood plasma binding of acebutolol and diacetolol in man.醋丁洛尔和双醋洛尔在人体中的血浆蛋白结合情况。
Br J Clin Pharmacol. 1980 Apr;9(4):395-7. doi: 10.1111/j.1365-2125.1980.tb01067.x.
5
Pharmacokinetics of acebutolol after intravenous bolus administration.静脉推注醋丁洛尔后的药代动力学。
Br J Clin Pharmacol. 1980 Feb;9(2):215-7. doi: 10.1111/j.1365-2125.1980.tb05837.x.
6
Pharmacokinetics and bioavailability of diacetolol, the main metabolite of acebutolol.醋丁洛尔的主要代谢产物双醋洛尔的药代动力学和生物利用度。
Eur J Clin Pharmacol. 1981 Mar;19(4):287-92. doi: 10.1007/BF00562806.
7
Pharmacokinetics in man of acebutolol and hydrochlorothiazide as single agents and in combination.醋丁洛尔和氢氯噻嗪单药及联合用药在人体中的药代动力学。
Eur J Clin Pharmacol. 1983;24(6):801-6. doi: 10.1007/BF00607091.
8
Quantitative relationships between structure and pharmacokinetics of beta-adrenoceptor blocking agents in man.人体内β-肾上腺素受体阻滞剂的结构与药代动力学之间的定量关系。
J Pharmacokinet Biopharm. 1984 Jun;12(3):263-87. doi: 10.1007/BF01061721.
9
Is there a relationship between the physical properties and cardioselectivity of beta-adrenoceptor antagonists?β-肾上腺素能受体拮抗剂的物理性质与心脏选择性之间存在关联吗?
Br J Clin Pharmacol. 1981 Apr;11(4):402-6. doi: 10.1111/j.1365-2125.1981.tb01145.x.
10
Acebutolol. A review of its pharmacological properties and therapeutic efficacy in hypertension, angina pectoris and arrhythmia.醋丁洛尔。其药理学特性及在高血压、心绞痛和心律失常治疗中的疗效综述。
Drugs. 1985 Jun;29(6):531-69. doi: 10.2165/00003495-198529060-00003.